Company: LHI
Filing Date: 2025-02-14
Form Type: DRS/A
Source: 0001213900-25-014190
Chunk: 184

Company: Living Homeopathy International Ltd.
Filing Date: 2025-02-14
Form: DRS/A
Chunk 184
---
 corporate governance standards. While we currently intend to voluntarily follow all Nasdaq corporate governance rules, including rules regarding committee structure and director independence, as described above, we mayin the future choose to take advantage of the following exemptions afforded to foreign private issuers:

| ● | Exemption from the requirement                                               
 that a majority of our board of directors consists of independent directors. |

| ● | Exemption from the requirement                                                                                               
 that our audit committee have a written charter addressing the audit committee’s responsibilities and authority as set forth 
 in Nasdaq Rule 5605(c)(1).                                                                                                   |

| ● | Exemption from the requirement                                                                                                
 that our compensation committee have a written charter addressing the remuneration committee’s responsibilities and authority 
 as set forth in Nasdaq Rule 5605(d).                                                                                          |

| ● | Exemption from the requirement                                                                                                             
 to have independent director oversight of director nominations and a formal written charter or board resolution addressing the nominations 
 process as set forth in Nasdaq Rule 5605(e).                                                                                               |

| ● | Exemption from the requirement                                                                                                     
 that we have a code of conduct applicable to all directors, officers and employees and from any requirement that we have a code of 
 conduct in compliance with Section 406 of the Sarbanes-Oxley Act of 2002.                                                          |

| ● | Exemption from the Nasdaq                                                                                                         
 rules applicable to domestic issuers requiring disclosure within four business days of any determination to grant a waiver of the 
 code of business conduct and ethics to directors and officers.                                                                    |

| ● | Exemption from the requirement                                                                                            
 to obtain shareholder approval for certain issuances of securities, including shareholder approval of stock option plans. |

<div align='center'>103</div>

| ● | Exemption from the requirements                                                                                                  
 governing the review and oversight of all “related party transactions,” as defined in Item 7.B of Form 20-F.                     |
| ● | Exemption from the requirement                                                                                                   
 that our board of directors shall have regularly scheduled meetings at which only independent directors are present as set forth 
 in Nasdaq Rule 5605(b)(2).                                                                                                       |

Although we mayrely on home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), we must comply with Nasdaq’s Notification of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640) and have an audit committee that satisfies Rule